Navigation Links
John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting
Date:7/18/2011

HACKENSACK, N.J. (July 18, 2011) Researchers from the John Theurer Cancer Center at Hackensack University Medical Center presented results from 14 cancer-related studies during the recently concluded American Society of Clinical Oncology (ASCO) Annual Meeting, which took place June 3 7, 2011 in Chicago. The studies examined new cancer treatments, ways to predict the best treatment outcomes, and patient quality of life issues.

"ASCO is a great venue for sharing best practices and learning about new treatment approaches we are proud to help contribute by presenting our recent scientific work," said Andre Goy, M.D., M.S., Chairman and Director and Chief of Lymphoma, John Theurer Cancer Center. "Our researchers will keep working to improve oncology and help develop some of the newest approaches to treating cancer. This will remain a priority for our cancer center."

Among other promising research, John Theurer Cancer Center investigators reported on a phase II study of carfilzomib, a new proteasome inhibitor to treat advanced multiple myeloma; the first phase III trial of anti-metabolite clofarabine against acute myelogenous leukemia; application of a new statistical model to predict mantle cell lymphoma survival and guide treatment choices; and a comparison of disease status and satisfaction with care among chronic myeloid leukemia patients.

"The innovative research we conduct brings tomorrow's treatments to our patients today," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services, John Theurer Cancer Center. "We have recently expanded our capabilities through the opening of an extraordinary new research and patient care facility, and it is our belief that this will enable us to further speed the pace of discovery and be even more prolific in our scientific publications."

Highlights of the Theurer Center presentations include:

PX-171-003-A1, an o
'/>"/>

Contact: Amy Leahing
Amy.leahing@zibbel.com
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. John Theurer Cancer Center BMT researchers highlight the importance of social support
2. Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds
3. Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
4. UT Southwestern research reveals that significantly more genetic mutations lead to colon cancer
5. Cancer gene therapy from camels
6. Cancer data not readily available for future research
7. UT faculty improving surgical outcomes for children, cancer patients
8. Study explains why men are at higher risk for stomach cancer
9. Stem cells restore cognitive abilities impaired by brain cancer treatment
10. PSA test for men could get a second life for breast cancer in women
11. Low dose naltrexone (LDN): Harnessing the bodys own chemistry to treat human ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... of how wildlife loss leads to conflict among people ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis of ... an interdisciplinary approach to tackle global biodiversity decline. , ... of the world,s people and provides protein for more ... come as no surprise that today,s unprecedented loss of ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... Acoustic disturbance has different effects on different species ... the Universities of Bristol and Exeter which tested ... sooner to a flying seagull predator model when ... observed in European minnows. , Lead author ... Sciences said: "Noise levels in many aquatic environments ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... Finland, have identified a blood-flow glucose consumption mismatch that ... study published in Clinical Cancer Research , a ... Based on these findings, they suggested that the ... important information about a tumor than just looking at ...
... can monitor chemical processes or equipment activity and then ... many facilities that could benefit from the use of ... instead, because the reliability, speed and security of the ... needs. The U.S. Department of Energy,s Savannah ...
... forest the boreal forest across large stretches of ... increasing threat, a team of international researchers has found. ... Canada, University of Adelaide in Australia and the National ... of existing boreal forests in order to secure biodiversity ...
Cached Biology News:Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness 2SRNL, automakers to develop high-performance wireless sensors networks 2SRNL, automakers to develop high-performance wireless sensors networks 3World's last great forest under threat: New study 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Conferee ... for Topics for Conferee Networking. These two-hour sessions provide ... to meet and resolve problems, discuss new techniques, or ... deadline to submit a topic for consideration is August ... pittcon.org . The Conferee Networking committee will review the ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... PharmaVentures announced today that it was delighted to act ... Canada as Merck & Co) to secure its deal with ... Roslin BioCentre, for the former MSD research facility in Newhouse, ... MSD, the Scottish Life Sciences community and the Scottish Government. ...
...   Reportlinker.com announces that a new market ... , Strategic Analysis of the Collagen ... http://www.reportlinker.com/p0760990/Strategic-Analysis-of-the-Collagen-Peptide-Market-in-the-United-States.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biomaterial This ... peptides. The historical period is from 2007, ...
... MECHANICSBURG, Pa., Jan. 18, 2012  Select Medical announced it ... Specialists, a well-known provider of physical therapy in the ... Select Medical family with a 25-year reputation for providing ... First Choice and another Select Medical brand known as ...
Cached Biology Technology:PharmaVentures Helps Secure Investor for Former MSD Research Site 2Strategic Analysis of the Collagen Peptide Market in the United States 2First Choice Rehabilitation Specialists Joins Select Medical 2